BCL11A and neoplasm: Either BAF155 methyl-defective mutants or CARM1 inhibition results in recruitment of BCL11A/PBAF to activate ISGs, leading to increased tumor infiltration of CD8+ T cells and enhanced T cell-mediated killing (Model in Figure 7F).